Medtronic's Growth Potential in Robotic Surgery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2026
0mins
Should l Buy MDT?
Source: Fool
- Strong Revenue Growth: Medtronic recently reported an 8.7% year-over-year revenue increase in its third quarter, highlighting robust performance in the medical device sector, particularly following FDA approval for its Hugo robotic surgery system, which is expected to drive market expansion.
- Stable Dividend Returns: With a dividend yield of 2.9% and a history of increasing payouts for 48 consecutive years, Medtronic not only demonstrates solid financial health but also provides a reliable income stream for investors, enhancing its attractiveness.
- R&D Investment and Patent Advantage: Medtronic invests approximately $2.7 billion annually in research and development and holds over 41,000 active patents, showcasing its deep commitment to innovation and technology, which ensures its competitive edge in the medical device market.
- Strategic Restructuring and Market Focus: Medtronic plans to spin off its diabetes division in early March, aiming for a valuation close to $8 billion, allowing the company to concentrate on faster-growing business areas and further enhance its overall market value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 90.900
Low
102.00
Averages
111.76
High
120.00
Current: 90.900
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Top 11 Stocks to Consider Buying Now: Schwab, Disney, and More
- Stock Market Trends: The stock market is experiencing a decline, presenting opportunities for investors to find bargains.
- Insider Purchases: Many of these bargains are being purchased by company insiders, indicating potential confidence in the stocks.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
Dividend Potential of Becton, Dickinson and Medtronic in Healthcare Sector
- Becton's Dividend History: Becton, Dickinson has increased its dividend for over 50 years, achieving a 2.4% yield, making it a solid investment choice in the healthcare sector; despite recent underperformance, its new product pipeline is expected to drive future growth.
- Medtronic's Growth Potential: Medtronic is on the verge of becoming a Dividend King with a 2.9% yield, having just launched surgical robots in the U.S. market, which is anticipated to create significant growth opportunities, particularly in the high-valuation surgical robotics sector.
- Low Investment Threshold: Investors can buy 5 shares of Becton or 10 shares of Medtronic for just $1,000, making these stocks ideal for small investors, especially given the current bearish market sentiment.
- Market Reaction Expectations: Although Becton was not recommended by The Motley Fool as a top investment, its long-standing dividend record and upcoming new products may attract long-term investors, particularly against the backdrop of sustained demand in the medical device industry.
See More
MiniMed Group's IPO Debut Shows Weak Performance
- IPO Financing Details: MiniMed Group raised $560 million through its IPO, yet opened at $19.05, reflecting a roughly 5% decline from the $20 offering price, indicating market caution regarding its prospects.
- Stock Performance Fluctuations: On its debut, MiniMed's stock further dropped to $18.95 shortly after opening, reflecting investor concerns about its market positioning and future profitability, which could impact the company's future financing capabilities.
- Market Valuation: Post-IPO, MiniMed is valued at $5.6 billion based on over 280.8 million shares outstanding, although this valuation fell short of market expectations, potentially limiting its future expansion plans.
- CEO Statement: MiniMed CEO Que Dallara remarked that today marks a defining moment for MiniMed as a standalone public company during the Nasdaq opening, and despite the lukewarm market response, the company must focus on its future strategic development.
See More
Medtronic Stock Enters Oversold Territory
- Oversold Indicator Analysis: Medtronic (MDT) shares fell to $90.17 on Friday, with an RSI of 28.7, indicating oversold conditions below the 30 threshold, suggesting potential buying opportunities for investors.
- Increased Dividend Yield: MDT's recent annual dividend of $2.84 per share translates to a 3.05% yield based on the current share price of $93.01, providing dividend investors with a higher yield amid falling stock prices.
- Market Sentiment Shift: Despite the decline in Medtronic's stock price, investors may view the 28.7 RSI as a sign that selling pressure is waning, prompting them to seek entry points for potential rebounds in the stock.
- Dividend History Consideration: While dividends are not always predictable, examining Medtronic's dividend history can help investors assess the likelihood of continued dividends, influencing their investment decisions.
See More
IYH ETF 52-Week Price Fluctuation Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.35 and a high of $67.63, with the latest trade at $63.36, indicating relative stability in the current market environment.
- Technical Analysis Tool: Comparing the recent share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in more informed investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their potential impact on underlying assets.
See More
Top 11 Stocks to Consider Buying Now: Schwab, Disney, and More
- Stock Market Trends: The stock market is experiencing a decline, presenting opportunities for investors to find bargains.
- Insider Purchases: Many of these bargains are being purchased by company insiders, indicating potential confidence in the stocks.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
Dividend Potential of Becton, Dickinson and Medtronic in Healthcare Sector
- Becton's Dividend History: Becton, Dickinson has increased its dividend for over 50 years, achieving a 2.4% yield, making it a solid investment choice in the healthcare sector; despite recent underperformance, its new product pipeline is expected to drive future growth.
- Medtronic's Growth Potential: Medtronic is on the verge of becoming a Dividend King with a 2.9% yield, having just launched surgical robots in the U.S. market, which is anticipated to create significant growth opportunities, particularly in the high-valuation surgical robotics sector.
- Low Investment Threshold: Investors can buy 5 shares of Becton or 10 shares of Medtronic for just $1,000, making these stocks ideal for small investors, especially given the current bearish market sentiment.
- Market Reaction Expectations: Although Becton was not recommended by The Motley Fool as a top investment, its long-standing dividend record and upcoming new products may attract long-term investors, particularly against the backdrop of sustained demand in the medical device industry.
See More
MiniMed Group's IPO Debut Shows Weak Performance
- IPO Financing Details: MiniMed Group raised $560 million through its IPO, yet opened at $19.05, reflecting a roughly 5% decline from the $20 offering price, indicating market caution regarding its prospects.
- Stock Performance Fluctuations: On its debut, MiniMed's stock further dropped to $18.95 shortly after opening, reflecting investor concerns about its market positioning and future profitability, which could impact the company's future financing capabilities.
- Market Valuation: Post-IPO, MiniMed is valued at $5.6 billion based on over 280.8 million shares outstanding, although this valuation fell short of market expectations, potentially limiting its future expansion plans.
- CEO Statement: MiniMed CEO Que Dallara remarked that today marks a defining moment for MiniMed as a standalone public company during the Nasdaq opening, and despite the lukewarm market response, the company must focus on its future strategic development.
See More
Medtronic Stock Enters Oversold Territory
- Oversold Indicator Analysis: Medtronic (MDT) shares fell to $90.17 on Friday, with an RSI of 28.7, indicating oversold conditions below the 30 threshold, suggesting potential buying opportunities for investors.
- Increased Dividend Yield: MDT's recent annual dividend of $2.84 per share translates to a 3.05% yield based on the current share price of $93.01, providing dividend investors with a higher yield amid falling stock prices.
- Market Sentiment Shift: Despite the decline in Medtronic's stock price, investors may view the 28.7 RSI as a sign that selling pressure is waning, prompting them to seek entry points for potential rebounds in the stock.
- Dividend History Consideration: While dividends are not always predictable, examining Medtronic's dividend history can help investors assess the likelihood of continued dividends, influencing their investment decisions.
See More
IYH ETF 52-Week Price Fluctuation Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.35 and a high of $67.63, with the latest trade at $63.36, indicating relative stability in the current market environment.
- Technical Analysis Tool: Comparing the recent share price to the 200-day moving average provides investors with deeper insights for technical analysis, aiding in more informed investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows (new units created) or outflows (old units destroyed), assessing their potential impact on underlying assets.
See More
